EMYRIA LIMITED — Capital/Financing Update 2021

Dec 29, 2021

ASX Announcement

30 Dec 2021

Emyria appoints Sixty Two Capital as corporate advisor

Emyria Limited (ASX: EMD) (Emyria or the Company), a data-backed drug development and care delivery company, is pleased to announce the appointment of Sixty Two Capital Pty Ltd (“Sixty Two Capital”) as corporate advisor. Sixty Two Capital is a boutique corporate advisory, brokerage and investment group specialising in supporting the growth of emerging companies listed on the ASX.

Sixty Two Capital will provide a range of corporate advisory services to the Company in connection with its capital markets requirements, investor relations and the identification of additional, value creating strategic opportunities.

Sixty Two Capital previously managed and corner-stoned two oversubscribed placements for Emyria in December 2020 and April 2021. (See ASX announcements dated 16 Dec 2020 and 21 April 2021)

In consideration for its services, the Company will:

• Pay Sixty Two Capital a monthly retainer of $10,000/ month over the next 12 months of involvement.

• Issue a total of 6 million Performance Advisory Options with an exercise price of $0.55, expiring 2 years from the date of issue. The Advisor options are subject to the vesting schedule below:

• 1 million unlisted options with a vesting condition that the EMD 10-day volume-weighted average price (VWAP) of EMD securities is at or above 60c (Tranche 1 Options).

• 2 million unlisted options with a vesting condition that the EMD 10-day VWAP is at or above 70c (Tranche 2 Options).

• 3 million unlisted options with a vesting condition that the EMD 10-day VWAP is at or above 90c (Tranche 3 Options).

• The arrangement can be terminated with 30 days written notice.

Emyria’s Managing Director, Dr. Michael Winlo said : “The team at Sixty Two Capital have been strong supporters of Emyria ever since their first corner-stoned placement in December 2020. Sixty Two Capital has a track record of supporting high growth client companies over the long-term. We are delighted to have their support as Emyria advances our major programs in the new year.”

Sixty Two Capital’s Director, Sufian Ahmad said : “Sixty Two Capital is delighted to assist Emyria in its next phase of growth as it seeks to develop registered medicines across its cannabinoid and psychedelic-assisted therapy portfolios. We believe that Emyria’s unique data-backed drug development platform has potential to bring new treatments to major patient populations globally, and in doing so, also generate significant returns for shareholders.”

1

==> picture [137 x 40] intentionally omitted <==

This announcement has been approved for release by the Managing Director of Emyria Limited.

For further information on Emyria , please contact:

	Dr. Michael Winlo	Lexi O’Halloran	Andrew Williams
	Managing Director	Media/Investor Relations	Media Relations
	1300 436 363	+ 61 (0) 404 577 076	+61 (0) 412 614 125
	mwinlo@emyria.com	lexi@janemorganmanagement.com.au	andreww@proflemedia.com.au

About Emyria (www.emyria.com)

Emyria Limited is a data-backed clinical drug development and care delivery company focused on accelerating treatment development and improving patient care.

Emyria’s Treatments target unmet needs and are focused on obtaining approval from major global regulators. Emyria’s drug development programs are informed by insights generated from extensive analysis of Emyria Data - deep, ethically-sourced clinical evidence that is gathered with patients across Emyria’s independent clinical services ( Emerald Clinics - www.emeraldclinics.com.au)

Emyria Data provides deep treatment insights and is therefore a source of unique IP, strategically designed drug development and personalised care programs.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.

2